Format
Items per page
Sort by

Send to:

Choose Destination

Links from GEO DataSets

Items: 19

1.
Full record GDS6083

Chronic lymphocytic leukemia cells response to the neutralization of inhibitor of apoptosis proteins

Analysis of chronic lymphocytic leukemia (CLL) cells treated with BV6, a Smac mimetic. CLL is characterized by B-lymphocyte accumulation, which is attributed to defective cell death. Inhibitor of apoptosis (IAP) proteins are highly expressed in CLL cells. Smac binds to and inhibits IAP proteins.
Organism:
Homo sapiens
Type:
Expression profiling by array, transformed count, 2 agent, 4 genotype/variation, 4 individual, 2 other, 2 time sets
Platform:
GPL570
Series:
GSE62533
12 Samples
Download data: CEL
DataSet
Accession:
GDS6083
ID:
6083
2.

Inhibitor of apoptosis proteins as promising therapeutic targets in chronic lymphocytic leukemia

(Submitter supplied) Inhibitor of apoptosis (IAP) proteins are expressed at high levels in CLL cells and may contribute to evasion of cell death leading to poor therapeutic outcome. Of note, prognostic unfavourable cases with e.g. non-mutated VH-status and TP53 mutation responded significantly better to BV6 than samples with unknown or favourable prognosis e.g. 13q deletion. The majority of cases with 17p deletion (10/12) and Fludarabine refractory cases were sensitive to BV6, indicating that BV6 acts independently of the p53 pathway. more...
Organism:
Homo sapiens
Type:
Expression profiling by array
Dataset:
GDS6083
Platform:
GPL570
12 Samples
Download data: CEL
Series
Accession:
GSE62533
ID:
200062533
3.

Inhibitor of apoptosis protein antagonist BV6 – potential for new combinatorial treatment strategies in acute myeloid leukemia

(Submitter supplied) Apoptosis is deregulated in most, if not all, cancers, including hematological malignancies. In this study, we wanted to test whether primary acute myeloid leukemia (AML) samples are sensitive for inhibitor of apoptosis (IAP) protein antagonist treatment in vitro, and which AML subgroup might profit most from such a novel therapeutic strategy. We treated diagnostic samples of 67 adult AML patients with either cytarabine (ara-C) or IAP antagonist BV6 and correlated sensitivity with clinical, cytogenetic and molecular markers, and expression levels of selected genes involved in apoptosis. more...
Organism:
Homo sapiens
Type:
Expression profiling by array
Platform:
GPL570
24 Samples
Download data: CEL
Series
Accession:
GSE46819
ID:
200046819
4.

BV6 induces an early wave of gene expression via NF-κB and AP-1 and a second wave via TNFα/TNFR1 signaling

(Submitter supplied) Smac mimetics are considered as promising cancer therapeutics, but little is yet known about how they alter gene expression. In this study we used an unbiased genome-wide expression array to investigate Smac mimetic BV6-induced gene regulation in breast cancer cell lines. Kinetic analysis revealed that BV6 alters gene expression in two waves. The first wave primarily involves NF-κB- and AP-1 families of transcription factors, while the second wave largely depends on tumor necrosis factor receptor 1 (TNFR1) signaling. more...
Organism:
Homo sapiens
Type:
Expression profiling by array
Platform:
GPL10558
48 Samples
Download data: TXT
Series
Accession:
GSE107912
ID:
200107912
5.

Deregulated apoptosis signaling in core binding factor leukemia differentiates clinically relevant, molecular marker independent subgroups

(Submitter supplied) Core binding factor (CBF) leukemias, characterized by translocations t(8;21) or inv(16)/t(16;16) targeting the core binding factor, constitute acute myeloid leukemia (AML) subgroups with favorable prognosis. However, about 40% of patients relapse, and the current classification system does not fully reflect this clinical heterogeneity. Previously, gene expression profiling (GEP) revealed two distinct CBF leukemia subgroups displaying significant outcome differences and identified apoptotic signaling, MAPKinase signaling and chemotherapy-resistance mechanisms among the most significant differentially regulated pathways. more...
Organism:
Homo sapiens
Type:
Expression profiling by array
Dataset:
GDS4285
Platform:
GPL570
12 Samples
Download data: CEL
Series
Accession:
GSE29883
ID:
200029883
6.
Full record GDS4285

Core binding factor-acute myeloid leukemia patients: mononuclear cells

Analysis of mononuclear cells isolated from untreated, CBF-AML patients representing t(8;21) and inv(16)/t(16;16) karyotypes. The CBF-AML samples exhibited differential sensitivity to treatment with ABT-737 and BV6. Results provide insight into molecular basis of sensitivity to inhibitor treatment.
Organism:
Homo sapiens
Type:
Expression profiling by array, transformed count, 11 age, 2 disease state, 2 gender, 12 individual, 5 other, 2 tissue sets
Platform:
GPL570
Series:
GSE29883
12 Samples
Download data: CEL
DataSet
Accession:
GDS4285
ID:
4285
7.

The mithralog EC-7072 is highly cytotoxic to chronic lymphocytic leukemia cells by targeting the B-cell receptor signaling pathway

(Submitter supplied) EC-7072, an analogue of Mithramycin A, exerts a direct cytotoxic effect on primary leukemic cells from patients with chronic lymphocytic leukemia (CLL) in vitro. To elucidate the underlying mechanisms mediating this effect, RNA sequencing was carried out employing total RNA from primary leukemic cells exposed to EC-7072. Data analysis revealed a dramatic impact of the compound on the transcriptional profile of CLL cells, unraveling a modulation of key mediators associated to homeostasis and survival of CLL cells, including B-cell receptor signaling. more...
Organism:
Homo sapiens
Type:
Expression profiling by high throughput sequencing
Platform:
GPL20301
16 Samples
Download data: XLSX
Series
Accession:
GSE123777
ID:
200123777
8.

Genome-Wide Expression Profiling of cultured B-CLL cells

(Submitter supplied) Increased survival of primary B-CLL cells cultured in high cell density: Evidence for activation of pathways also induced by stromal cells.
Organism:
Homo sapiens
Type:
Expression profiling by array
Platforms:
GPL9244 GPL9243
29 Samples
Download data: GPR
Series
Accession:
GSE18192
ID:
200018192
9.

BRD4 profiling identifies critical Chronic Lymphocytic Leukemia oncogenic circuits and reveals sensitivity to PLX51107, a novel structurally distinct BET inhibitor

(Submitter supplied) This SuperSeries is composed of the SubSeries listed below.
Organism:
Homo sapiens
Type:
Expression profiling by array; Genome binding/occupancy profiling by high throughput sequencing
Platforms:
GPL18573 GPL17586 GPL20301
58 Samples
Download data: BED, CEL, CHP
Series
Accession:
GSE109593
ID:
200109593
10.

BRD4 profiling identifies critical Chronic Lymphocytic Leukemia oncogenic circuits and reveals sensitivity to PLX51107, a novel structurally distinct BET inhibitor [expression profiling]

(Submitter supplied) Bromodomain and extra-terminal (BET) family proteins are key regulators of gene expression in cancer. Herein, we utilize BRD4 profiling to identify critical pathways involved in pathogenesis of chronic lymphocytic leukemia (CLL). BRD4 is over-expressed in CLL and is enriched proximal to genes up-regulated or de novo expressed in CLL with known function in disease pathogenesis and progression. These genes, including key members of the BCR signaling pathway, provide rationale for this therapeutic approach to identify new targets in alternative types of cancer. more...
Organism:
Homo sapiens
Type:
Expression profiling by array
Platform:
GPL17586
9 Samples
Download data: CEL, CHP
Series
Accession:
GSE109587
ID:
200109587
11.

BRD4 profiling identifies critical Chronic Lymphocytic Leukemia oncogenic circuits and reveals sensitivity to PLX51107, a novel structurally distinct BET inhibitor [ChIP-seq]

(Submitter supplied) Bromodomain and extra-terminal (BET) family proteins are key regulators of gene expression in cancer. Herein, we utilize BRD4 profiling to identify critical pathways involved in pathogenesis of chronic lymphocytic leukemia (CLL). BRD4 is over-expressed in CLL and is enriched proximal to genes up-regulated or de novo expressed in CLL with known function in disease pathogenesis and progression. These genes, including key members of the BCR signaling pathway, provide rationale for this therapeutic approach to identify new targets in alternative types of cancer. more...
Organism:
Homo sapiens
Type:
Genome binding/occupancy profiling by high throughput sequencing
Platforms:
GPL20301 GPL18573
49 Samples
Download data: BED, XLSX
Series
Accession:
GSE109411
ID:
200109411
12.

The isopeptidase inhibitor 2cPE triggers proteotoxic stress and ATM activation in chronic lymphocytic leukemia cells.

(Submitter supplied) In this study we investigated changes in gene expression induced by 2cPE (a non-selective isopeptidase inhibitor) in leukemia cells isolated from 10 different patients suffering of B-cell chronic lymphocytic leukemia. We compared 2cPE induced changes in mRNA levels with those induced by bortezomib, another well characterized proteasome inhibitor. Both inhibitors trigger apoptosis in leukemia cells.
Organism:
Homo sapiens
Type:
Expression profiling by array
Platform:
GPL20650
26 Samples
Download data: CEL, TXT
Series
Accession:
GSE74514
ID:
200074514
13.

SLAMF1/CD150 regulates chemotaxis, autophagy and therapy responses in chronic lymphocytic leukemia patients

(Submitter supplied) This work shows that signaling-lymphocytic-activation-molecule-1 (SLAMF1), a co-stimulatory molecule and a microbial sensor, is expressed by normal CD19+/CD5+ B-lymphocytes. Its expression is lost in a subset of patients with chronic lymphocytic leukemia (CLL) characterized by an aggressive form of the disease, with shorter time to first treatment and overall survival. Silencing of SLAMF1 in the CLL-like Mec-1 cell line (constitutively SLAMF1+) modulated pathways connected to cell migration, cytoskeletal organization and intracellular vesicle formation/recirculation. more...
Organism:
Homo sapiens
Type:
Expression profiling by array
Platform:
GPL10558
6 Samples
Download data: TXT
Series
Accession:
GSE69165
ID:
200069165
14.

Enhancer profiling of chronic lymphocytic leukemia cells

(Submitter supplied) Enhancer profiling has emerged as a powerful approach for discovering the cis-regulatory elements that define transcriptional core regulatory circuits. Characteristic biochemical and biophysical attributes of chromatin mark active enhancer elements, which can be leveraged with genome-wide assay technologies for discovery. This includes chromatin immunoprecipitation followed by sequencing (ChIP-seq) for histone H3 acetylated lysine 27 (H3K27ac). more...
Organism:
Homo sapiens
Type:
Expression profiling by high throughput sequencing; Genome binding/occupancy profiling by high throughput sequencing
Platform:
GPL18573
36 Samples
Download data: BEDGRAPH, XLSX
Series
Accession:
GSE119744
ID:
200119744
15.

TpoR Agonist signaling in AML primary cells

(Submitter supplied) Biologic characterization of SB-559457 (SB), a non-peptidyl hydrazone class of thrombopoietin receptor (Mpl) agonist, revealed toxicity towards human leukemia cells. Anti-proliferative effects followed by significant, non-apoptotic, cell death within 72 hours occurred in 24/26 AML, 0/6 ALL, and 3/6 CML patient samples exposed to SB, but not recombinant human thrombopoietin (rhTpo), in liquid suspension culture. more...
Organism:
Homo sapiens
Type:
Expression profiling by array
Dataset:
GDS3606
Platform:
GPL571
10 Samples
Download data: CEL, CHP
Series
Accession:
GSE18673
ID:
200018673
16.
Full record GDS3606

Myeloid leukemia cell response to thrombopoietin receptor agonist SB-559457 in vitro

Analysis of primary cultured myeloid leukemia cells treated with recombinant human thrombopoietin or the thrombopoietin receptor agonist SB-559457 (SB). SB is toxic to leukemia cells. Results provide insight into the mechanism of action of SB.
Organism:
Homo sapiens
Type:
Expression profiling by array, count, 2 agent, 5 individual sets
Platform:
GPL571
Series:
GSE18673
10 Samples
Download data: CEL, CHP
DataSet
Accession:
GDS3606
ID:
3606
17.

Overexpression of UGT2B17 in MEC1 and JVM2 leukemia cell lines

(Submitter supplied) UGT2B17 is a recently identified molecular marker for poor prognosis in Chronic Lymphocytic Leukemia (CLL), which is the most prevalent adult leukemia subtype in the western world. The goal of this study was to determine the effects of UGT2B17 expression in leukemia cells and to find molecular pathways associated with high UGT2B17 expression. We characterized the effects of UGT2B17 in two leukemia cell lines (MEC1 and JVM2) overexpressing a functional UGT2B17 enzyme. more...
Organism:
Homo sapiens
Type:
Expression profiling by high throughput sequencing
Platforms:
GPL16791 GPL11154
12 Samples
Download data: TXT
Series
Accession:
GSE121626
ID:
200121626
18.

Expression data from tumour celllines and non-tumour cells.

(Submitter supplied) Chronic lymphocytic leukemia shows a variable clinical course which is associated with distinct alterations such as chromosomal aberrations, gene mutations or IGHV mutation status. Refining biologic categories may help to improve clinical management with available and future treatment, lymphoma/leukemia celllines and non-tumour cells of the microenvironment can be used for models to better categorize biologic CLL entities. more...
Organism:
Homo sapiens
Type:
Expression profiling by array
Platform:
GPL5175
43 Samples
Download data
Series
Accession:
GSE126699
ID:
200126699
19.

Expression data from CLL patient samples investigated to define biologic heterogeneity.

(Submitter supplied) Chronic lymphocytic leukemia shows a variable clinical course which is associated with distinct alterations such as chromosomal aberrations, gene mutations or IGHV mutation status. Refining biologic categories may help to improve clinical management with available and future treatment approaches. We used Affymetrix Exon 1.0 ST microarrays to investigate differences in CLL biology.
Organism:
Homo sapiens
Type:
Expression profiling by array
Platform:
GPL5175
726 Samples
Download data
Series
Accession:
GSE126595
ID:
200126595
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

db=gds|term=|query=1|qty=2|blobid=MCID_6169f727799dd072b8523295|ismultiple=true|min_list=5|max_list=20|def_tree=20|def_list=|def_view=|url=/Taxonomy/backend/subset.cgi?|trace_url=/stat?
   Taxonomic Groups  [List]
Tree placeholder
    Top Organisms  [Tree]

Find related data

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
Support Center